• Return to Headlines

Mallinckrodt is Among the Companies in the Pharmaceuticals Industry With the Lowest EBITDA Growth (MNK, DEPO, PAHC, PRGO, LCI)

By Shiri Gupta

Below are the three companies in the Pharmaceuticals industry with the lowest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Mallinckrodt ranks lowest with a EBITDA growth of -0.1%. Depomed Inc is next with a EBITDA growth of 5.6%. Phibro Animal-A ranks third lowest with a EBITDA growth of 10.4%.

Perrigo Co Plc follows with a EBITDA growth of 13.3%, and Lannett Co Inc rounds out the bottom five with a EBITDA growth of 15.5%.

SmarTrend recommended that subscribers consider buying shares of Mallinckrodt on May 15th, 2018 as our technology indicated a new Uptrend was in progress when shares hit $15.78. Since that recommendation, shares of Mallinckrodt have risen 97.1%. We continue to monitor Mallinckrodt for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest ebitda growth mallinckrodt depomed inc phibro animal-a perrigo co plc lannett co inc

Ticker(s): MNK DEPO PAHC PRGO LCI